Cargando…

Advanced Phase I/II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Gemcitabine-resistant Metastatic Pancreatic Cancer

Rexin-G, a nonreplicative pathology-targeted retroviral vector bearing a cytocidal cyclin G1 construct, was tested in a phase I/II study for gemcitabine-resistant pancreatic cancer. The patients received escalating doses of Rexin-G intravenously from 1 × 10(11) colony-forming units (cfu) 2–3× a week...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chawla, Sant P, Chua, Victoria S, Fernandez, Lita, Quon, Dorris, Blackwelder, William C, Gordon, Erlinda M, Hall, Frederick L
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2839309/ https://www.ncbi.nlm.nih.gov/pubmed/19826403 http://dx.doi.org/10.1038/mt.2009.228

Ejemplares similares

Phase I/II and Phase II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Chemotherapy-resistant Sarcoma and Osteosarcoma
por: Chawla, Sant P, et al.
Publicado: (2009)

Rexin-G(®), a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report
por: Kim, Seth, et al.
Publicado: (2017)

A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer
por: Chawla, Sant P., et al.
Publicado: (2018)

Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with DeltaRex-G: A case report and literature review
por: Morse, Michael A., et al.
Publicado: (2021)

Cell cycle checkpoint control: The cyclin G1/Mdm2/p53 axis emerges as a strategic target for broad-spectrum cancer gene therapy - A review of molecular mechanisms for oncologists
por: Gordon, Erlinda M., et al.
Publicado: (2018)

Exploiting Oncogenic Drivers along the CCNG1 Pathway for Cancer Therapy and Gene Therapy
por: Al-Shihabi, Ahmad, et al.
Publicado: (2018)

Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer
por: Monti, Daniel A., et al.
Publicado: (2012)

Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)
por: Chawla, Sant P., et al.
Publicado: (2023)

Gemcitabine plus S-1 for metastatic pancreatic cancer
por: Zhu, Hong, et al.
Publicado: (2018)

Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives
por: Gordon, Erlinda M., et al.
Publicado: (2016)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2016)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2016)

SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma
por: Gordon, Erlinda Maria, et al.
Publicado: (2023)

Ultrasound- and Microbubble-Assisted Gemcitabine Delivery to Pancreatic Cancer Cells
por: Bjånes, Tormod, et al.
Publicado: (2020)

Raltitrexed–eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer
por: Reni, M, et al.
Publicado: (2006)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2018)

Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
por: Nakamura, K, et al.
Publicado: (2005)

Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
por: Nakamura, K, et al.
Publicado: (2006)

Dosing Schedules of Gemcitabine and nab-Paclitaxel for Older Adults With Metastatic Pancreatic Cancer
por: Winer, Arthur, et al.
Publicado: (2021)

Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer
por: Perez, Kimberly, et al.
Publicado: (2023)

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
por: Stathopoulos, G P, et al.
Publicado: (2006)

nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
por: Tehfe, Mustapha, et al.
Publicado: (2016)

The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence
por: Prejac, Juraj, et al.
Publicado: (2022)

Preoperative gemcitabine based chemo-radiotherapy in locally advanced non metastatic pancreatic adenocarcinoma
por: Maximous, Doaa W, et al.
Publicado: (2009)

Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis
por: Goulart, Bernardo HL, et al.
Publicado: (2009)

A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma
por: Hu, Jing, et al.
Publicado: (2011)

Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
por: Corrie, P. G., et al.
Publicado: (2020)

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
por: Wilbur, H. Catherine, et al.
Publicado: (2023)

Nimotuzumab Concurrent with Gemcitabine as First-Line Treatment of Locally Advanced or Metastatic Pancreatic Adenocarcinoma
por: Sánchez, Yamirka, et al.
Publicado: (2023)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

Erratum to: nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
por: Tehfe, Mustapha, et al.
Publicado: (2016)

Health-related quality of life for gemcitabine and nab-paclitaxel plus radiotherapy versus gemcitabine and S-1 plus radiotherapy in patients with metastatic pancreatic cancer
por: Zhu, Xiaofei, et al.
Publicado: (2018)

Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine
por: Quinn, Bridget A., et al.
Publicado: (2016)

Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma
por: Bukhari, Nedal, et al.
Publicado: (2021)

Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
por: Grierson, Patrick M, et al.
Publicado: (2022)

Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma
por: Piquemal, David, et al.
Publicado: (2023)

Palmitoyl Carnitine-Anchored Nanoliposomes for Neovasculature-Specific Delivery of Gemcitabine Elaidate to Treat Pancreatic Cancer
por: Patel, Akanksha, et al.
Publicado: (2022)

Clinically Meaningful Responses to Sequential Gemcitabine-Based Chemotherapy Regimens in a Patient with Metastatic Pancreatic Cancer
por: Klimant, Eiko, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_kn7rublf7v9un2p1udfmb27427